The US National Institute of Allergy and Infectious Diseases (NIAID) has announced three contracts to develop vaccines for infectious diseases and biological threats that could be used in a terror attack.
The studies will involve a dengue vaccine delivered by a needle-free device, an orally delivered anthrax vaccine and an anthrax vaccine delivered in conjunction with an adjuvant.
Inviragen will develop the tetravalent dengue vaccine, which will be delivered using a needle-free system developed by PharmaJet.
Inviragen has been granted an initial award of $1.8m, with a possibility of further $15.5m over the next five years depending upon the achievement of clinical milestones.
PaxVax will develop and test two formulations of orally delivered anthrax vaccine, one of which will be used to conduct a Phase I clinical trial.
Emergent Biosolutions will also develop and test an anthrax vaccine, which will be combination of licensed anthrax vaccine BioThrax and an adjuvant.
Emergent has been granted an initial award of $9.1m, with the potential for $28.7m of further funding over the next four years if milestones are met.